{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T02:34:28Z","timestamp":1793068468402,"version":"4.5.0"},"reference-count":41,"publisher":"Society of Nuclear Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.2967\/jnumed.123.265429","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T13:05:31Z","timestamp":1695906331000},"page":"1965-1971","source":"Crossref","is-referenced-by-count":38,"title":["[\n                    <sup>123<\/sup>\n                    I]CC1: A PARP-Targeting, Auger Electron\u2013Emitting Radiopharmaceutical for Radionuclide Therapy of Cancer"],"prefix":"10.2967","volume":"64","author":[{"given":"Chung Ying","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Guibbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gemma","family":"Dias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Destro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"O\u2019Neill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Veal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Lau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mosley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas C.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Gouverneur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart","family":"Cornelissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"2023120108101135000_64.12.1965.1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2766"},{"key":"2023120108101135000_64.12.1965.2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-2753"},{"key":"2023120108101135000_64.12.1965.3","doi-asserted-by":"publisher","DOI":"10.1177\/1947601910383418"},{"key":"2023120108101135000_64.12.1965.4","doi-asserted-by":"publisher","DOI":"10.2174\/157016310793360657"},{"key":"2023120108101135000_64.12.1965.5","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s41181-019-0075-2","article-title":"Auger electrons for cancer therapy: a review","volume":"4","author":"Ku","year":"2019","journal-title":"EJNMMI Radiopharm Chem."},{"key":"2023120108101135000_64.12.1965.6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1002\/jlcr.3847","article-title":"A one-pot radiosynthesis of [18F]PARPi","volume":"63","author":"Wilson","year":"2020","journal-title":"J Labelled Comp Radiopharm."},{"key":"2023120108101135000_64.12.1965.7","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.118.213223"},{"key":"2023120108101135000_64.12.1965.8","doi-asserted-by":"crossref","first-page":"3668","DOI":"10.1007\/s00259-022-05835-4","article-title":"Imaging PARP with [18F]rucaparib in pancreatic cancer models","volume":"49","author":"Chan","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2023120108101135000_64.12.1965.9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/acsptsci.0c00206","article-title":"PARP targeted alpha-particle therapy enhances response to PD-1 immune-checkpoint blockade in a syngeneic mouse model of glioblastoma","volume":"4","author":"Dabagian","year":"2021","journal-title":"ACS Pharmacol Transl Sci."},{"key":"2023120108101135000_64.12.1965.10","doi-asserted-by":"crossref","first-page":"565","DOI":"10.3390\/biomedicines9050565","article-title":"Radiosynthesis and evaluation of talazoparib and its derivatives as PARP-1-targeting agents","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomedicines."},{"key":"2023120108101135000_64.12.1965.11","doi-asserted-by":"crossref","first-page":"15690","DOI":"10.1021\/acs.jmedchem.1c00903","article-title":"DoE optimization empowers the automated preparation of enantiomerically pure [18F]talazoparib and its in\u00a0vivo evaluation as a PARP radiotracer","volume":"64","author":"Bowden","year":"2021","journal-title":"J Med Chem."},{"key":"2023120108101135000_64.12.1965.12","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.243287"},{"key":"2023120108101135000_64.12.1965.13","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3389\/fphar.2020.00170","article-title":"Poly(ADP-ribose)polymerase (PARP) inhibitors and radiation therapy","volume":"11","author":"Jannetti","year":"2020","journal-title":"Front Pharmacol."},{"key":"2023120108101135000_64.12.1965.14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2014.01.019"},{"key":"2023120108101135000_64.12.1965.15","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2016161929"},{"key":"2023120108101135000_64.12.1965.16","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1001\/jamaoncol.2020.0334","article-title":"Positron emission tomography imaging of poly-(adenosine diphosphate-ribose) polymerase 1 expression in breast cancer: a nonrandomized clinical trial","volume":"6","author":"McDonald","year":"2020","journal-title":"JAMA Oncol."},{"key":"2023120108101135000_64.12.1965.17","doi-asserted-by":"crossref","first-page":"e146592","DOI":"10.1172\/jci.insight.146592","article-title":"In vivo visualization of PARP inhibitor pharmacodynamics","volume":"6","author":"McDonald","year":"2021","journal-title":"JCI Insight."},{"key":"2023120108101135000_64.12.1965.18","doi-asserted-by":"publisher","DOI":"10.1007\/s11307-015-0904-y"},{"key":"2023120108101135000_64.12.1965.19","first-page":"vdaa119","article-title":"Preclinical and first-in-human-brain-cancer applications of [18F]poly (ADP-ribose) polymerase inhibitor PET\/MR","volume":"2","author":"Young","year":"2020","journal-title":"Neurooncol Adv."},{"key":"2023120108101135000_64.12.1965.20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-3484"},{"key":"2023120108101135000_64.12.1965.21","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1021\/acs.molpharmaceut.1c00323","article-title":"PARP-targeted Auger therapy in p53 mutant colon cancer xenograft mouse models","volume":"18","author":"Wilson","year":"2021","journal-title":"Mol Pharm."},{"key":"2023120108101135000_64.12.1965.22","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13550-022-00932-9","article-title":"PARP targeted Auger emitter therapy with [125I]PARPi-01 for triple-negative breast cancer","volume":"12","author":"Sankaranarayanan","year":"2022","journal-title":"EJNMMI Res."},{"key":"2023120108101135000_64.12.1965.23","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.2967\/jnumed.117.205054","article-title":"PARP-1-targeted radiotherapy in mouse models of glioblastoma","volume":"59","author":"Jannetti","year":"2018","journal-title":"J Nucl Med."},{"key":"2023120108101135000_64.12.1965.24","first-page":"4019","article-title":"In vitro targeted radionuclide therapy studies of a PARP-targeted Meitner-Auger electron emitting radiopharmaceutical [abstract]","volume":"63","author":"Hoffman","year":"2022","journal-title":"J Nucl Med."},{"key":"2023120108101135000_64.12.1965.25","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1021\/acs.orglett.8b00232","article-title":"Rapid Cu-catalyzed [211At]astatination and [125I]iodination of boronic esters at room temperature","volume":"20","author":"Reilly","year":"2018","journal-title":"Org Lett."},{"key":"2023120108101135000_64.12.1965.26","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-18-0837"},{"key":"2023120108101135000_64.12.1965.27","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.3390\/ijms24043083","article-title":"Preclinical efficacy of a PARP-1 targeted Auger-emitting radionuclide in prostate cancer","volume":"24","author":"Sreekumar","year":"2023","journal-title":"Int J Mol Sci."},{"key":"2023120108101135000_64.12.1965.28","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2006.339"},{"key":"2023120108101135000_64.12.1965.29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-2440"},{"key":"2023120108101135000_64.12.1965.30","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.113.131037"},{"key":"2023120108101135000_64.12.1965.31","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.263253"},{"key":"2023120108101135000_64.12.1965.32","doi-asserted-by":"crossref","first-page":"114690","DOI":"10.1016\/j.ejmech.2022.114690","article-title":"Current status and progress in using radiolabelled PARP-1 inhibitors for imaging PARP-1 expression in tumours","volume":"242","author":"Wang","year":"2022","journal-title":"Eur J Med Chem."},{"key":"2023120108101135000_64.12.1965.33","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.261894"},{"key":"2023120108101135000_64.12.1965.34","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97992"},{"key":"2023120108101135000_64.12.1965.35","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1158\/1078-0432.CCR-22-1602","article-title":"[18F]fluorthanatrace ([18F]FTT) PET imaging of PARP-inhibitor drug-target engagement as a biomarker of response in ovarian cancer: a pilot study","volume":"29","author":"Pantel","year":"2023","journal-title":"Clin Cancer Res."},{"key":"2023120108101135000_64.12.1965.36","doi-asserted-by":"crossref","first-page":"6029","DOI":"10.3390\/molecules25246029","article-title":"PARP theranostic Auger emitters are cytotoxic in BRCA mutant ovarian cancer and viable tumors from ovarian cancer patients enable ex-vivo screening of tumor response","volume":"25","author":"Riad","year":"2020","journal-title":"Molecules."},{"key":"2023120108101135000_64.12.1965.37","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.nucmedbio.2016.08.007","article-title":"Iodinated benzimidazole PARP radiotracer for evaluating PARP1\/2 expression in\u00a0vitro and in\u00a0vivo","volume":"43","author":"Anderson","year":"2016","journal-title":"Nucl Med Biol."},{"key":"2023120108101135000_64.12.1965.38","doi-asserted-by":"crossref","first-page":"108312","DOI":"10.1016\/j.nucmedbio.2022.108312","article-title":"A radioiodinated rucaparib analogue as an Auger electron emitter for cancer therapy","volume":"116\u2013117","author":"Destro","year":"2023","journal-title":"Nucl Med Biol."},{"key":"2023120108101135000_64.12.1965.39","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s11307-020-01497-6","article-title":"[18F]AZD2461, an insight on difference in PARP binding profiles for DNA damage response PET imaging","volume":"22","author":"Guibbal","year":"2020","journal-title":"Mol Imaging Biol."},{"key":"2023120108101135000_64.12.1965.40","doi-asserted-by":"publisher","DOI":"10.1126\/science.aax6367"},{"key":"2023120108101135000_64.12.1965.41","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13550-022-00940-9","article-title":"Correlation between molar activity, injection mass and uptake of the PARP targeting radiotracer [18F]olaparib in mouse models of glioma","volume":"12","author":"Chan","year":"2022","journal-title":"EJNMMI Res."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.123.265429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T11:11:55Z","timestamp":1701429115000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.123.265429"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12,1]]},"published-print":{"date-parts":[[2023,12]]}},"alternative-id":["10.2967\/jnumed.123.265429"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.123.265429","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}